Global Prostate Cancer Therapeutics Market is valued USD 11.77 Billion in 2019 and is projected is to exhibit 9.57 % CAGR during the forecast period. The market is projected to be around USD 22.32 Billion by 2026. The market is driven by the rapid increasing awareness among people regarding prostate cancer.

Prostate cancer is diagnosed when the cell in the prostate gland starts growing abnormally and uncontrollably. Prostate cancer can be treated by surgery, radiation, hormone therapy, chemotherapy, and others. The treatment for prostate cancer is decided by the stage of cancer. Professionals such as urologists, radiation oncologists, and medical oncologists are professional doctors who treat prostate cancer.
Prostate Cancer Therapeutics Market Dynamics
Increasing awareness among people regarding prostate cancer along with technological advancement in screening and diagnostic tests, rising preferences of healthy living will increase the geriatric population are expected to drive the growth of the prostate cancer therapeutics market in the forecast period. However, the key success factor driving prostate cancer therapeutics uptake is attributable to advancements in oncology, leading to the early diagnosis of prostate cancer.

At the same time, increasing the cost of the treatment and the adverse impact of treatment along with less success rate will hamper the growth of the prostate cancer therapeutics market during the forecast period. However, the limited number of players, increasing pharmaceutical expenditure will further create new opportunities for the growth of the prostate cancer therapeutics market over the period.
Prostate Cancer Therapeutics Market Insight
Based on the region, North America is expected to dominate the market of a prostate cancer therapeutics market, due to rising prevalence and high mortality rate of prostate cancer in the U.S. are the primary reasons responsible for the dominance of North America in the market. Also, this region is witnessing high investment in R&D for the development of more novel immunotherapies and targeted drug therapies to treat such tumors. Additionally, Asia Pacific is expected to be the fastest-growing market over the forecast period. Rising awareness of such tumors would primarily boost growth. Governments of various countries in this region are playing a vital role in creating awareness through programs and online portals that provide detailed information regarding screening and diagnosis through PSA blood tests and DRE for male patients above 50 years of age.
Prostate Cancer Therapeutics Market Segmentation
The global Prostate Cancer Therapeutics Market is segmented into therapy, distribution channel, and region. On the basis of the therapy the market is divided into hormone therapy, targeted therapy, chemotherapy, biologic therapy. Based on distribution channel the market is segmented into hospital pharmacies, online sales, retail pharmacies, others. And based on the geography the market is further segregated into North America, Latin America, Europe and Asia Pacific.
Prostate Cancer Therapeutics Market Competitive Landscape
The key players in Prostate Cancer Therapeutics Market are listed as Bayer AG, Johnson & Johnson, Ipsen Group, Amgen, Inc., Endo Pharmaceuticals, Inc., AbbVie, Inc., Pfizer, Inc., AstraZeneca, Sanofi, Sanpower Group, and Other.